| All Releases |
|---|
 |
Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Feb 26, 2010
|
8.4 KB
|
| |
SUNNYVALE, Calif., Feb 26, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, announced that the Company will be participating at the RBC Capital Markets Healt...
|
|
|
Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
Feb 11, 2010
|
29.6 KB
|
| |
SUNNYVALE, Calif., Feb 11, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its second fiscal quarter ended December 31, 2009.
Upon the completion of a drug supply agreement with Servier in the quarter ended December 31, 2009, the company began recognizing revenue under GAAP from...
|
|
|
Pharmacyclics Announces Date of Second Quarter Fiscal 2010 Financial Results and Conference Call
Feb 8, 2010
|
9.5 KB
|
| |
SUNNYVALE, Calif., Feb 08, 2010 /PRNewswire via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will report financial results for the second fiscal quart...
|
|
|
Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
Dec 7, 2009
|
14.0 KB
|
| |
NEW ORLEANS and SUNNYVALE, Calif., Dec 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced interim data from a Phase I study of their novel orally administered Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) or ch...
|
|
|
Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
Dec 6, 2009
|
13.5 KB
|
| |
NEW ORLEANS and SUNNYVALE, Calif., Dec 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced interim results from a Phase I/II study showing safety and clinical activity in patients with relapsed / recurrent non-Hodgkin's Lymphoma (NHL) treated with its HDAC inhibitor PCI-24781 as a single age...
|
|
|
Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
Dec 3, 2009
|
10.5 KB
|
| |
SUNNYVALE, Calif., Dec 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will host a webcast and conference call on, Tues...
|
|
|
Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Nov 12, 2009
|
12.2 KB
|
| |
SUNNYVALE, Calif., Nov 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.
A material clinical u...
|
|
|
Pharmacyclics to Present at Merriman Curhan Ford's Investor Summit 2009
Nov 9, 2009
|
9.1 KB
|
| |
SUNNYVALE, Calif., Nov 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Dr. David Loury, Vice President, Preclinical Develo...
|
|
|
Pharmacyclics Reports First Quarter Fiscal 2010 Financial Results
Oct 29, 2009
|
13.1 KB
|
| |
SUNNYVALE, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its first fiscal quarter ended September 30, 2009. The net loss for the first quarter of fiscal 2010 was $4.8 million, or $0.12 per share, compared to a net loss of $6.5 million, or $0.25 per shar...
|
|
|
Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results
Sep 17, 2009
|
26.6 KB
|
| |
SUNNYVALE, Calif., , Sept 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net l...
|
|
|
Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
Sep 14, 2009
|
8.3 KB
|
| |
SUNNYVALE, Calif., Sept 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will report financial results for the fourth qu...
|
|
|
Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
Sep 3, 2009
|
8.7 KB
|
| |
SUNNYVALE, Calif., Sept 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Dr. Glenn Rice, President and COO, will provide a ...
|
|
|
Pharmacyclics, Inc. Rights Offering Oversubscribed
Aug 5, 2009
|
10.8 KB
|
| |
SUNNYVALE, Calif., Aug 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today the preliminary results of its rights offering to purchase up to 22,500,000 shares of the Company's common stock at a subscription price of $1.28 per share, which expired as of 5:00 p.m., EDT, on July 31, 2009. The Co...
|
|
|
Pharmacyclics Announces Subscription Price for Rights Offering
Jul 15, 2009
|
10.9 KB
|
| |
SUNNYVALE, Calif., July 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) (the "Company") announced today that it has set a subscription price of $1.28 per share of its common stock for its previously announced rights offering. An aggregate of approximately 18,750,000 million shares of common stock will b...
|
|
|
Pharmacyclics Sets Record Date for Rights Offering
Jul 7, 2009
|
9.9 KB
|
| |
SUNNYVALE, Calif., July 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has set the close of trading on July 15, 2009 as the record date for its upcoming Rights Offering. To participate in the rights offering, shares of Pharmacyclics would have to be purchased on or before July 10...
|
|
|
Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
Jun 5, 2009
|
8.6 KB
|
| |
SUNNYVALE, Calif., June 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated disease and cancer, today announced that Glenn Rice, President and COO will present on Wednes...
|
|
|
Pharmacyclics Files Registration Statement for Rights Offering
Jun 1, 2009
|
11.2 KB
|
| |
SUNNYVALE, Calif., June 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it filed a registration statement on Form S-3 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing stockholders. The rights offering will be made through the distribution...
|
|
|
Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results
Apr 23, 2009
|
14.6 KB
|
| |
SUNNYVALE, Calif., April 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its third fiscal quarter ended March 31, 2009. The net loss for the third quarter of fiscal 2009 was $6.7 million, or $0.25 per share, compared to a net loss of $7.0 million, or $0.27 per share,...
|
|
|
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
Apr 17, 2009
|
13.4 KB
|
| |
SUNNYVALE, Calif., April 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has entered into a global strategic alliance with Servier, the leading French independent pharmaceutical company. The alliance will focus on the research, development, and commercialization of Pharmacyclics'...
|
|
|
Pharmacyclics Updates Positive Clinical Responses in its PCI-24781 Clinical Program Targeting HDAC
Apr 16, 2009
|
14.6 KB
|
| |
SUNNYVALE, Calif., Apr 16, 2009 (BUSINESS WIRE) -- Pharmacyclics, Inc. (NASDAQ:PCYC) today announced an update to its
clinical programs targeting histone deacetylase (HDAC) with its drug
candidate PCI-24781 that is currently in multiple clinical trials for
treating various solid and hematologic tumors. In addition, the Compa...
|
|
|
